agomelatine

1. Basic Product Identification INN Name: Agomelatine Therapeutic Class: Antidepressant Pharmacological Class: Melatonergic antidepressant ATC Code: N06AX22 Primary Indication: Major Depressive Disorder (MDD) Route of Administration: Oral Dosage Form: Tablet (usually film-coated) 2. Therapeutic Knowledge Used for Major Depressive Disorder in adults Improves: Mood Sleep cycle Anxiety symptoms associated with depression Unique advantage: No sexual dysfunction (unlike SSRIs) No withdrawal syndrome Not first-line in all countries due to liver safety monitoring requirement 3. Mechanism of Action (MOA) Agomelatine works through a dual mechanism: Melatonin receptor agonist MT1 receptor → improves sleep initiation MT2 receptor → improves circadian rhythm resynchronization Serotonin receptor antagonist Blocks 5-HT2C receptors Increases dopamine and norepinephrine release in frontal cortex ???? Result: Circadian rhythm normalization Antidepressant effect via dopamine/norepinephrine increase 4. Pharmacokinetics (ADME) Absorption: Rapid but low bioavailability (~5%) Tmax: ~1–2 hours Protein binding: ~95% Metabolism: Extensive hepatic (CYP1A2 mainly, also CYP2C9) Half-life: ~1–2 hours (short, but effect is functional not plasma-based) Excretion: Mainly urine as metabolites ⚠️ CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are contraindicated. 5. Dosage & Administration Starting dose: 25 mg once daily at bedtime Dose increase: 50 mg once daily if insufficient response after 2 weeks Administration: Bedtime (important for circadian action) Liver monitoring: Baseline LFT mandatory Regular monitoring during treatment 6. Formulation Knowledge Immediate release film-coated tablets Typical strengths: 25 mg 50 mg Excipients: Lactose monohydrate Povidone Crospovidone Magnesium stearate Film coating polymers (HPMC, PEG, titanium dioxide) 7. Raw Materials Knowledge API: Agomelatine (synthetic melatonergic compound) Key raw intermediates: Naphthalene derivatives Acetamide intermediates Critical impurity controls: N-desmethyl agomelatine Oxidative degradation products 8. Manufacturing Process Knowledge Typical API synthesis involves: Multi-step organic synthesis Formation of naphthalene core structure Amide coupling reactions Purification via recrystallization / chromatography Tablet manufacturing: Direct compression or wet granulation Low-dose API → high content uniformity control critical Sensitive to moisture and light 9. Analytical & QC Knowledge Key tests: Assay (HPLC) Related substances / impurities Dissolution testing (USP/Ph.Eur) Content uniformity (critical due to low dose) Stability-indicating methods Residual solvents (GC) Stability indicating methods must detect: Oxidation products Photodegradation products 10. Regulatory Knowledge Approved in EU (EMA), India, several other countries Not FDA-approved (US) Requires Risk Management Plan (RMP) in EU Mandatory: Liver function monitoring warnings Controlled distribution in some regions due to hepatotoxicity risk 11. Storage & Stability Store below 25°C Protect from: Moisture Light Shelf life: typically 2–3 years Stability concerns: Oxidation Photodegradation 12. Packaging Knowledge Alu-Alu blister preferred (moisture protection) Strip packaging also used Secondary packaging includes: Liver monitoring warning leaflet Patient information leaflet 13. Safety & Toxicology Key risks: Hepatotoxicity (major concern) Elevated liver enzymes Rare severe liver injury Contraindications: Liver impairment CYP1A2 inhibitors (strong) Side effects: Headache Dizziness Fatigue GI disturbances 14. Market & Commercial Knowledge Positioning: “Circadian Bulk agomelatine API Supplier in Cordoba rhythm correcting antidepressant” Competitors: SSRIs (sertraline, escitalopram) SNRIs (venlafaxine, duloxetine) Market advantage: Sleep improvement without benzodiazepines Market limitation: Liver monitoring reduces adoption 15. Intellectual Property (IP) Original developer: Servier (France) Patent status: Mostly expired in many regions Generics available in multiple markets Still protected via: Formulation patents (in some countries) Process patents (limited) 16. Environmental & EHS Knowledge Pharmaceutical waste must be treated as hazardous Avoid API release into wastewater Solvent recovery systems recommended Worker safety: PPE required during API handling Dust control essential 17. Export Documentation Knowledge Typical requirements: COA (Certificate of Analysis) GMP Certificate DMF (Drug Master File) / ASMF Stability data package MSDS (Material Safety Data Sheet) Shipping validation documents 18. Business Development Knowledge Target buyers: Generic pharmaceutical companies CNS-focused formulators Key selling points: Differentiated antidepressant mechanism Patent-expired API opportunities Risks: Regulatory hesitation due to hepatotoxicity Strategy: Position as “premium niche antidepressant API” 19. Advanced Technical Knowledge Circadian rhythm pharmacology is central Not a monoamine reuptake inhibitor (unlike SSRIs) Unique chronobiological drug class Requires chronotherapy-based dosing concept 20. AI & Digital Knowledge (Modern Pharma) Applications: Predict liver toxicity using AI models Stability prediction via ML degradation models Supply chain forecasting for CNS drugs Digital pharmacovigilance tracking of liver injury reports 21. Sales Team Product Knowledge Checklist Sales team must know: Indication (MDD only) Dose timing (bedtime critical) Liver monitoring requirement CYP1A2 interactions Key differentiator: sleep normalization Not habit-forming Market limitations (hepatotoxicity monitoring) 22. Most Important Technical Documents DMF / ASMF COA (API + finished product) Stability reports (ICH) Bioequivalence studies Safety pharmacology reports Impurity profile report Regulatory approval dossier (EU SmPC) 23. Ultimate Pharma Product Mastery Summary Agomelatine is: A dual melatonin agonist + serotonin antagonist antidepressant Highly unique in circadian rhythm correction Limited by liver safety monitoring Strong niche product in CNS segment Ideal for differentiation vs SSRIs/SNRIs